| Ovarian Cancer |
NCT00979082: Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer |
|
|
| Active, not recruiting | 3 | 186 | US | carboplatin, glutathione, paclitaxel, placebo | North Central Cancer Treatment Group, National Cancer Institute (NCI) | Chemotherapeutic Agent Toxicity, Fallopian Tube Cancer, Neurotoxicity, Ovarian Cancer, Pain, Peripheral Neuropathy, Primary Peritoneal Cavity Cancer | 10/14 | | | |
NCT02159820: Lower Dose Decitabine (DAC)-Primed TC (Carboplatin-Paclitaxel) Regimen in Ovary Cancer |
|
|
| Recruiting | 2/3 | 500 | RoW | Decitabine (DTC Arm), Paclitaxel and Carboplatin (TC Arm) | Chinese PLA General Hospital | Primary Malignant Neoplasm of Ovary, FIGO Stages II to IV | 06/24 | 06/24 | | |
NCT00436735: Nelfinavir in Treating Patients With Metastatic, Refractory, or Recurrent Solid Tumors |
|
|
| Active, not recruiting | 1 | 45 | US | midazolam hydrochloride, nelfinavir mesylate, gene expression analysis, polymerase chain reaction, protein expression analysis, immunoenzyme technique, immunologic technique, laboratory biomarker analysis, mass spectrometry | National Cancer Institute (NCI) | Colorectal Cancer, Gastrointestinal Carcinoid Tumor, Head and Neck Cancer, Islet Cell Tumor, Lung Cancer, Metastatic Cancer, Neuroendocrine Carcinoma of the Skin, Ovarian Cancer, Pheochromocytoma, Sarcoma, Unspecified Adult Solid Tumor, Protocol Specific | | | | |
NCT02066883: Prognostic Potential Cell Surface Markers CD47 / CD27 / CD8 and Pim-kinase in Patients With Hematologic Malignancies or Solid Tumors |
|
|
| Recruiting | N/A | 150 | RoW | | Cancer Centre of Monoclonal Therapy, LLC | Solid Tumor, Ovarian Cancer, Non-small Cell Lung Cancer, Chronic Lymphocytic Leukemia, Burkitt's Lymphoma | 07/15 | 02/17 | | |
NCT02090127: Protocol to Allow Continued Access of Ficlatuzumab to P05538 Patient |
|
|
| No Longer Available | N/A | | US | ficlatuzumab, AV-299, SCH 900105 | AVEO Pharmaceuticals, Inc. | Mullerian Mixed Tumor of Ovary | | | | |
NCT01000259: Study of Tumor Tissue Samples From Patients Who Have Undergone Surgery for Advanced Stage III or Stage IV Ovarian Epithelial Cancer |
|
|
| Recruiting | N/A | 174 | US | Laboratory Biomarker Analysis | Gynecologic Oncology Group, National Cancer Institute (NCI) | Stage IIIA Ovarian Cancer, Stage IIIB Ovarian Cancer, Stage IIIC Ovarian Cancer, Stage IV Ovarian Cancer | 01/00 | | | |
NCT01445275: Cost of Cancer Risk Management in Women at Elevated Genetic Risk for Ovarian Cancer Who Participated on GOG-0199 |
|
|
| Not yet recruiting | N/A | 2605 | US | Evaluation of Cancer Risk Factors, cancer risk factors evaluation, Medical Chart Review, Chart Review, Study of Socioeconomic and Demographic Variables | Gynecologic Oncology Group, National Cancer Institute (NCI) | Fallopian Tube Carcinoma, Hereditary Breast and Ovarian Cancer Syndrome, Ovarian Carcinoma, Primary Peritoneal Carcinoma | 01/00 | | | |